UA91180C2 - Клетка бактерий mycobacterium bovis, которая является уреазодефицитной, и применение данной клетки для изготовления живой вакцины против туберкулеза - Google Patents

Клетка бактерий mycobacterium bovis, которая является уреазодефицитной, и применение данной клетки для изготовления живой вакцины против туберкулеза

Info

Publication number
UA91180C2
UA91180C2 UAA200510351A UAA200510351A UA91180C2 UA 91180 C2 UA91180 C2 UA 91180C2 UA A200510351 A UAA200510351 A UA A200510351A UA A200510351 A UAA200510351 A UA A200510351A UA 91180 C2 UA91180 C2 UA 91180C2
Authority
UA
Ukraine
Prior art keywords
cell
antituberculous
urease
vaccine
deficient
Prior art date
Application number
UAA200510351A
Other languages
English (en)
Ukrainian (uk)
Inventor
Леандер Гроде
Штефан Х.Е. Кауфманн
Бербель Раупах
Юрген Хесс
Original Assignee
Макс-Планк-Гезельшафт Цур Фьордерунг Дер Виссеншафтен Ай.Еф.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Макс-Планк-Гезельшафт Цур Фьордерунг Дер Виссеншафтен Ай.Еф. filed Critical Макс-Планк-Гезельшафт Цур Фьордерунг Дер Виссеншафтен Ай.Еф.
Publication of UA91180C2 publication Critical patent/UA91180C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится к клетке бактерий Mycobacterium bovis, которая является уреазодефицитной и содержит молекулу рекомбинантной нуклеиновой кислоты, которая кодирует домен выхода из фаголизосомы и полипептид, который может вызывать иммунную реакцию у млекопитающего. Изобретение также относится к способу получения данной клетки, фармацевтической композиции, которая ее содержит, а также к применению данной клетки для изготовления живой вакцины против туберкулеза.
UAA200510351A 2003-04-23 2004-04-23 Клетка бактерий mycobacterium bovis, которая является уреазодефицитной, и применение данной клетки для изготовления живой вакцины против туберкулеза UA91180C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46464403P 2003-04-23 2003-04-23

Publications (1)

Publication Number Publication Date
UA91180C2 true UA91180C2 (ru) 2010-07-12

Family

ID=33310924

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200510351A UA91180C2 (ru) 2003-04-23 2004-04-23 Клетка бактерий mycobacterium bovis, которая является уреазодефицитной, и применение данной клетки для изготовления живой вакцины против туберкулеза

Country Status (24)

Country Link
US (2) US7988980B2 (ru)
EP (1) EP1618128B1 (ru)
JP (1) JP4662925B2 (ru)
KR (1) KR101101263B1 (ru)
CN (1) CN1798762B (ru)
AT (1) ATE473238T1 (ru)
AU (1) AU2004232485B2 (ru)
BR (1) BRPI0409789B8 (ru)
CA (1) CA2523084C (ru)
CU (1) CU23608A3 (ru)
CY (1) CY1110793T1 (ru)
DE (1) DE602004028000D1 (ru)
DK (1) DK1618128T3 (ru)
ES (1) ES2344698T3 (ru)
HK (1) HK1091217A1 (ru)
HR (1) HRP20100395T1 (ru)
MX (1) MXPA05011360A (ru)
PL (1) PL1618128T3 (ru)
PT (1) PT1618128E (ru)
RU (1) RU2342400C2 (ru)
SI (1) SI1618128T1 (ru)
UA (1) UA91180C2 (ru)
WO (1) WO2004094469A1 (ru)
ZA (1) ZA200508276B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2523084C (en) * 2003-04-23 2012-09-04 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Tuberculosis vaccine with improved efficacy
EP1649869A1 (en) * 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
CA2589204C (en) 2004-12-01 2013-10-29 Aeras Global Tb Vaccine Foundation Recombinant bcg strains with enhanced ability to escape the endosome
CN101969976A (zh) * 2008-01-11 2011-02-09 美国政府健康与人类服务部秘书处 针对分枝杆菌的多肽疫苗和接种策略
WO2011031139A1 (en) 2009-09-09 2011-03-17 Universiteit Utrecht Holding B.V. An ataq protein or a part thereof as a vaccine
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
WO2012026820A2 (en) 2010-08-27 2012-03-01 Pantarhei Bioscience B.V. Immunotherapeutic method for treating prostate cancer
PT2618837T (pt) * 2010-09-20 2018-10-18 Vakzine Projekt Man Gmbh Micobactérias recombinantes como vacina para uso em humanos
SG190222A1 (en) 2010-11-10 2013-06-28 Leti Sl Lab New adjuvant
CA2822715C (en) 2010-12-21 2019-04-30 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Determination of the efficacy of an anti-mycobacterial vaccination
KR101832019B1 (ko) * 2010-12-21 2018-02-23 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 백신으로서의 재조합 마이코박테리움
RU2520078C1 (ru) * 2013-04-25 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
EP3090757A1 (en) 2015-05-04 2016-11-09 Vakzine Projekt Management GmbH Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
US20180256633A1 (en) 2015-09-18 2018-09-13 Rijksuniversiteit Groningen Long chain inulin for stimulating an immune response
KR101825439B1 (ko) * 2016-04-15 2018-02-05 배재대학교 산학협력단 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법
GB2572903B (en) * 2017-04-07 2022-10-12 Chengdu Yongan Pharm Co Ltd Recombinant BCG overexpressing phoP-phoR
US10261777B2 (en) * 2017-07-25 2019-04-16 Aurora Labs Ltd. Detecting anomalies online using histograms of ECU processing activity
RU2678175C1 (ru) * 2018-03-16 2019-01-23 федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ гриппа им. А.А. Смородинцева" Минздрава России) Рекомбинантный штамм вируса гриппа A/PR8/HK-NS80E85A, экспрессирующий фрагменты антигенов ESAT-6 и Ag85A M.tuberculosis, для получения векторной вакцины против туберкулеза
CN111979162B (zh) * 2019-05-22 2024-02-13 上海市公共卫生临床中心 重组卡介苗菌株、其制备方法和用途
WO2021228768A1 (en) 2020-05-11 2021-11-18 Vakzine Projekt Management Gmbh Prevention of infectious diseases by modulating the immune system
WO2021228363A1 (en) 2020-05-11 2021-11-18 Vakzine Projekt Management Gmbh Prevention of infectious diseases by modulating the immune system
EP4122491A1 (en) 2021-07-22 2023-01-25 Vakzine Projekt Management GmbH Recombinant microbacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma
EP4373519A1 (en) 2021-07-22 2024-05-29 Serum Life Science Europe GmbH Recombinant mycobacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0902086A1 (en) * 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
CA2523084C (en) * 2003-04-23 2012-09-04 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Tuberculosis vaccine with improved efficacy

Also Published As

Publication number Publication date
CN1798762B (zh) 2010-04-28
US20120027794A1 (en) 2012-02-02
CA2523084A1 (en) 2004-11-04
KR20050114281A (ko) 2005-12-05
ATE473238T1 (de) 2010-07-15
EP1618128A1 (en) 2006-01-25
DK1618128T3 (da) 2010-10-18
JP4662925B2 (ja) 2011-03-30
CY1110793T1 (el) 2015-06-10
SI1618128T1 (sl) 2010-11-30
US20070134267A1 (en) 2007-06-14
PT1618128E (pt) 2010-10-13
CU23608A3 (es) 2010-12-08
HRP20100395T1 (hr) 2010-09-30
DE602004028000D1 (de) 2010-08-19
ES2344698T3 (es) 2010-09-03
RU2005136354A (ru) 2006-03-20
HK1091217A1 (en) 2007-01-12
JP2007524367A (ja) 2007-08-30
BRPI0409789B8 (pt) 2021-05-25
CN1798762A (zh) 2006-07-05
RU2342400C2 (ru) 2008-12-27
WO2004094469A1 (en) 2004-11-04
BRPI0409789A (pt) 2006-05-30
PL1618128T3 (pl) 2010-12-31
ZA200508276B (en) 2006-06-28
US8545854B2 (en) 2013-10-01
AU2004232485A1 (en) 2004-11-04
KR101101263B1 (ko) 2012-01-04
MXPA05011360A (es) 2005-11-28
BRPI0409789B1 (pt) 2018-10-16
CA2523084C (en) 2012-09-04
US7988980B2 (en) 2011-08-02
AU2004232485B2 (en) 2009-11-26
EP1618128B1 (en) 2010-07-07

Similar Documents

Publication Publication Date Title
UA91180C2 (ru) Клетка бактерий mycobacterium bovis, которая является уреазодефицитной, и применение данной клетки для изготовления живой вакцины против туберкулеза
IL175021A0 (en) Chromatin insulator, its preparation and use in protein expression
WO2005121331A3 (en) Truncated galnact2 polypeptides and nucleic acids
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
WO2005121332A3 (en) Truncated st6galnaci polypeptides and nucleic acids
MX2009010800A (es) Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
EP2363460A3 (en) Acid fungal proteases
EE05633B1 (et) Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine
UA107329C2 (ru) Туберкулезный белок rv2386c, композиция, содержащая его, и применения
TR201816277T4 (tr) Çapraz-tür-spesifik bağlama alanı.
AU4078599A (en) Expression vectors for stimulating an immune response and methods of using the same
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
ATE522541T1 (de) Bakterielle adhäsine konformere
NZ585777A (en) Compositions and methods of enhancing immune responses to eimeria
WO2003082183A3 (en) Protein-based streptococcus pneumoniae vaccines
MY150226A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use
BR0309570A (pt) Fatores camp quiméricos para vacinação contra infecção por streptococcus
GB0320020D0 (en) Improved formulation for providing an enteric coating material
EP4095152A3 (en) Engineered ribosomal promoters for protein production in microorganisms
UA101140C2 (ru) Комбинация рекомбинантной микобактерии и биологически активного агента как вакцины
NZ596501A (en) Casb7439 constructs
PT1290160E (pt) Polipeptideos pellino humanos
PL352484A1 (en) Equine granulocyte-macrophage colony-stimulating factor (gm-csf)
ATE434940T1 (de) Verfahren zur verbesserung der immunfunktion bei säugern unter verwendung von lactobacillus reuteri-stämmen
BR0115646A (pt) Composição, dispositivo de liberação de partìculas, uso de uma composição, e, método para intensificar uma resposta imune contra um antìgeno de interesse em um paciente